These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14732939)

  • 1. Combined estrogen-progestin oral contraceptives.
    Sutherland SE; Munarriz RM; Goldstein I
    N Engl J Med; 2004 Jan; 350(3):307-8; author reply 307-8. PubMed ID: 14732939
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral contraceptives vs injectable progestin in their effect on sexual behavior.
    Schaffir JA; Isley MM; Woodward M
    Am J Obstet Gynecol; 2010 Dec; 203(6):545.e1-5. PubMed ID: 20800828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined estrogen-progestin oral contraceptives.
    Martinelli I; Battaglioli T; Mannucci PM
    N Engl J Med; 2004 Jan; 350(3):307-8; author reply 307-8. PubMed ID: 14724315
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive.
    Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Sparacino L; Cianci A
    Contraception; 2005 Jul; 72(1):19-23. PubMed ID: 15964287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
    Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
    Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study.
    Schilling LH
    Contraception; 2009 Mar; 79(3):241; author reply 241-2. PubMed ID: 19185682
    [No Abstract]   [Full Text] [Related]  

  • 9. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
    Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
    Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen dermatitis: treatment with progestin-only pill.
    Randall K; Steele R
    Arch Dermatol; 2005 Jun; 141(6):792-3. PubMed ID: 15967937
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral contraceptives in migraine.
    Allais G; Gabellari IC; De Lorenzo C; Mana O; Benedetto C
    Expert Rev Neurother; 2009 Mar; 9(3):381-93. PubMed ID: 19271947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice.
    Loder EW; Buse DC; Golub JR
    Headache; 2005 Mar; 45(3):224-31. PubMed ID: 15836597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of thrombosis related to hormone therapy.
    Sandset PM; Høibraaten E; Eilertsen AL; Dahm A
    Thromb Res; 2009; 123 Suppl 2():S70-3. PubMed ID: 19217481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudotumour cerebri in a young obese woman on oral contraceptives.
    Finsterer J; Kues EW; Brunner S
    Eur J Contracept Reprod Health Care; 2006 Sep; 11(3):237-40. PubMed ID: 17056456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.
    Shifren JL; Davis SR; Moreau M; Waldbaum A; Bouchard C; DeRogatis L; Derzko C; Bearnson P; Kakos N; O'Neill S; Levine S; Wekselman K; Buch A; Rodenberg C; Kroll R
    Menopause; 2006; 13(5):770-9. PubMed ID: 16932240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in hormonal contraception.
    Erkkola R
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):547-53. PubMed ID: 18007132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners.
    Guida M; Di Spiezio Sardo A; Bramante S; Sparice S; Acunzo G; Tommaselli GA; Di Carlo C; Pellicano M; Greco E; Nappi C
    Hum Reprod; 2005 Apr; 20(4):1100-6. PubMed ID: 15608030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception.
    Mishell DR; Guillebaud J; Westhoff C; Nelson AL; Kaunitz AM; Trussell J; Davis AJ
    Contraception; 2007 Jan; 75(1):4-10. PubMed ID: 17161116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.